Introduction

SABA over-use in asthma is harmful for patients and the environment. The SENTINEL Project utilised a co-designed intervention to identify and address SABA over-use with the aim of improving patient outcomes and reducing the environmental impact of asthma and its treatment. SENTINEL Plus is the scaled implementation of the same co-designed intervention across Primary Care organisations in England.

Aims and Objectives

To characterise the first 25 primary care sites to adopt SENTINEL Plus and assess changes in prescribing practice post-implementation.

Methods

Prescribing data (openprescribing.net) were analysed for the months July 2020 to October 2022 inclusive. Post-SENTINEL Plus implementation data were compared with the matched months pre-implementation.

Results

The first 25 SENTINEL Plus adopting practices had mean 11.2 months follow-up data post-implementation. 10,481 fewer SABA inhalers (p<0.05) and 5,978 more ICS containing inhalers (p?0.001) were prescribed post implementation than would be expected if prescribing had remained unchanged from pre-SENTINEL Plus levels. Practice and prescribing data are presented in Table 1.

Conclusions

SENTINEL Plus implementation across geographically diverse primary care practices in England was associated with a significant reduction in SABA and increased ICS prescribing, concordant with improved asthma prescribing practice.